ArticleEJHaem2022

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.

Filippo Spriano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.